Author

Agency for Quality

OpenAlex ID: A5083535563

Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). EUnetHTA report

2018 · Dental, EUnetHTA Pharmaceutical Benefits Agency, et al.

Works count: 1

Citation count:

H-index:

I10-index: